Comparison

Sermorelin vs CJC-1295 DAC

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

Sermorelin

Also: Geref, GRF 1-29

Preclinical

A truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.

Growth HormoneAnimal Studies
CJC-1295 DAC

Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC

Clinical Trials

A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.

Growth HormoneHuman Trials

Key Comparison Insights

  • Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
  • CJC-1295 DAC has stronger research evidence (Human Trials) compared to Sermorelin (Animal Studies).

Detailed Comparison

AttributeSermorelinCJC-1295 DAC
CategoryGrowth HormoneGrowth Hormone
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionSermorelin is bioidentical to the active portion of endogenous GHRH. It stimulates the pituitary's natural production and release of growth hormone, maintaining normal feedback mechanisms and pulsatile GH release patterns.CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation.
Common Dosing
200-500 mcg before bed
Once daily, typically before bed
Limited community data available
See research protocols
AdministrationSubcutaneous injection at bedtimeSubcutaneous injection
Typical Duration3-6 months typical8-12 weeks typical
Best Time to TakeBefore bed (fasted)Before bed or morning (fasted)
Possible Side Effects
May vary by individual
  • Facial flushing (most common)
  • Injection site reactions
  • Headache
  • Nausea
  • Dizziness
  • +4 more
  • Generally well-tolerated
  • Injection site reactions
  • Facial flushing
  • Water retention
  • Headache
  • +3 more
Research SummaryExtensive clinical research from FDA approval process. Studies demonstrate restoration of youthful GH levels, improved sleep quality, increased lean body mass, and enhanced recovery. Generally preserves natural GH axis better than exogenous GH.Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient.

Frequently Asked Questions: Sermorelin vs CJC-1295 DAC

What is the difference between Sermorelin and CJC-1295 DAC?

Sermorelin is a growth hormone peptide that a truncated analog of natural ghrh containing the first 29 amino acids. previously fda-approved for pediatric gh deficiency, now used off-label for adult hormone optimization. CJC-1295 DAC is a growth hormone peptide that a long-acting ghrh analog with drug affinity complex for extended half-life. provides sustained gh elevation for days with single injection. The main differences lie in their mechanisms of action and clinical applications.

Which is better, Sermorelin or CJC-1295 DAC?

Neither is universally "better" - the choice depends on your specific goals. Sermorelin is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can Sermorelin and CJC-1295 DAC be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using Sermorelin and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles

Educational Information Only

This comparison of Sermorelin and CJC-1295 DAC is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.